Chicago, IL - The 2014 ASCO Annual Meeting - Audience at the Melanoma/Skin Cancers Oral Abstract Session at the American Society of Clinical Oncology Annual Meeting here today, Monday June 2, 2014. More than 30,000 physicians, researchers, health care professionals, cancer survivors and patient advocates are expected to attend the 50th Anniversary meeting at the McCormick Convention Center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Todd Buchanan 2014 Technical Questions: todd@medmeetingimages.com
Chicago, IL - The 2014 ASCO Annual Meeting - Mario Sznol, MD presents Abstract #LBA9003^: "Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)," at the Melanoma/Skin Cancers Oral Abstract Session at the American Society of Clinical Oncology Annual Meeting here today, Monday June 2, 2014. More than 30,000 physicians, researchers, health care professionals, cancer survivors and patient advocates are expected to attend the 50th Anniversary meeting at the McCormick Convention Center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Todd Buchanan 2014 Technical Questions: todd@medmeetingimages.com
